Reto Ossola, Group Leader for Biomarket Research at Biognosys, joins Helen Winsor from Pharma IQ, to discuss phase I clinical development. He outlines where he sees the main challenges in biomarker development at the moment and discusses some key ways to address the cost-efficiency pressures. The interview also takes a look at partnerships - Ossola offers some best practice tips on assessing and working with a CRO, together with a summary of the main challenges in selecting partners and ensuring a good working relationship when entering into discovery outsourcing and collaborations. Ossola also outlines some of the different types of partnerships that Biognosys has been involved in and what he thinks is the best approach. Finally, we look at the hype in the market about identification and validation of biomarkers, and discuss whether this is expected to provide benefit within phase I trials. Haven’t got the technology to listen to the podcast? Download the transcript here: Improving Biomarker Development Work Flow in Phase I Clinical Development.

[inlinead]